scispace - formally typeset
J

Jennifer A. Flegg

Researcher at University of Melbourne

Publications -  75
Citations -  4037

Jennifer A. Flegg is an academic researcher from University of Melbourne. The author has contributed to research in topics: Malaria & Medicine. The author has an hindex of 24, co-authored 60 publications receiving 3445 citations. Previous affiliations of Jennifer A. Flegg include Monash University & University of Oxford.

Papers
More filters
Journal ArticleDOI

Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Elizabeth A. Ashley, +82 more
TL;DR: Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing, and the incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission.
Journal ArticleDOI

Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia

TL;DR: Replication and validation studies are needed to refine the location of loci responsible for artemisinin resistance and to understand the mechanism behind it; however, two SNPs on chromosomes 10 and 13 may be useful markers of delayed parasite clearance in surveillance for artesunate resistance in Southeast Asia.
Journal ArticleDOI

Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator

TL;DR: The parasite clearance estimator provides a consistent, reliable and accurate method to estimate the lag phase and malaria parasite clearance rate and could be used to detect early signs of emerging resistance to artemisinin derivatives and other compounds which affect ring-stage clearance.
Journal ArticleDOI

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

Jane Achan, +89 more
- 01 Dec 2013 - 
TL;DR: In this paper, the influence of different dosing schedules on Dihydroartemisinin-piperaquine (DP) clinical efficacy was investigated, and a multivariable model was used to identify risk factors for parasite recrudescence.